<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:7pt Arial, sans-serif; }
 .font1 { font:9pt Arial, sans-serif; }
 .font2 { font:10pt Arial, sans-serif; }
 .font3 { font:16pt Arial, sans-serif; }
 .font4 { font:13pt Times New Roman, serif; }

</style>
</head>
<body><a name="caption1"></a>
<h6><a name="bookmark0"></a><span class="font3"><a name="bookmark1"></a>Overall Positioning</span></h6>
<p><a name="bookmark2"></a><span class="font2" style="font-weight:bold;"><a name="bookmark3"></a>Major Pharma</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">□ &nbsp;&nbsp;&nbsp;On valuation, the Major Pharma sector has rerated but remains at a steep discount to the broader market and we see an opportunity for this gap to narrow further</span></p></li>
<li>
<p><span class="font1">□ &nbsp;&nbsp;&nbsp;While the 2026-2029 patent cycle has been top of mind for investors, pipeline progression and business development across the group leave us with only a modest decline in top line for the sector over this timeframe.</span></p></li></ul>
<ul style="list-style:none;"><li>
<p><span class="font1">□ &nbsp;&nbsp;&nbsp;Further, we see an upward bias to numbers based on a mix of further pipeline de-risking/capital deployment.</span></p></li>
<li>
<p><span class="font1">□ &nbsp;&nbsp;&nbsp;Our recommendations are skewed towards names that we believe have the longest runways for EPS growth (LLY) orthose trading at a steep discount (ABBV/BMY)</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;font-style:italic;">■ &nbsp;&nbsp;&nbsp;Favorite ideas: ABBV, LLY, BMY</span></p></li></ul>
<p><a name="bookmark4"></a><span class="font2" style="font-weight:bold;"><a name="bookmark5"></a>Animal Health</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">■ &nbsp;&nbsp;&nbsp;The sector exits the pandemic with improved companion animal dynamics and signs of a recovery within the livestock market. Along these lines, we view Animal Health’s longer-term fundamentals as the most attractive in our coverage with a clear upward bias to sector estimates.</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;font-style:italic;">■ &nbsp;&nbsp;&nbsp;Favorite idea: ZTS</span></p></li></ul>
<p><a name="bookmark6"></a><span class="font2" style="font-weight:bold;"><a name="bookmark7"></a>Spec Pharma</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">□ &nbsp;&nbsp;&nbsp;We still do not see a compelling reason to broadly own the group. That said, we have several interesting stories trading at attractive valuations despite what we view as well positioned assets.</span></p></li>
<li>
<p><span class="font2" style="font-weight:bold;font-style:italic;">□ &nbsp;&nbsp;&nbsp;Favorite idea: HZNP</span></p>
<div>
<p><span class="font0" style="font-weight:bold;">2</span></p>
</div><br clear="all"></li></ul>
<p><a name="bookmark8"></a><span class="font4"><a name="bookmark9"></a>JPMorgan</span></p>
<div>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
</div><br clear="all">
</body>
</html>